Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03290326 : tACS for Amyloid-? Reduction in Alzheimer's Disease
AgesMin: 45 Years Max: N/A
Inclusion Criteria:

- Clinical Diagnosis of mild AD defined by: Clinical Dementia Rating (CDR) = 0.5-1, Mini
Mental State Examination (MMSE) >/= 20, Demonstration or history of memory impairments

- Amyloid positive PET imaging

- At least 45 years old

- On a stable dose of medications for memory loss including cholinesterase inhibitors
(e.g. donepezil, rivastigmine or memantine) as defined as 6 consecutive weeks of
treatment at an unchanging dose

- Intelligence Quotient (IQ) > 85 as determined by the Wechsler Test of Adult Reading
(WTAR) and no history of intellectual disability

Exclusion Criteria:

- Current history of poorly controlled migraines including chronic medication for
migraine prevention

- Current or past history of any neurological disorder other than dementia, such as
epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or
intracranial brain lesions; and history of previous neurosurgery or head trauma that
resulted in residual neurologic impairment.

- Past or current history of major depression, bipolar disorder or psychotic disorders,
or any other major psychiatric condition.

- Contraindication for undergoing MRI or receiving Transcranial Magnetic Stimulation
(TMS) or tACS,

• History of fainting spells of unknown or undetermined etiology that might constitute

- History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or
immediate (1st degree relative) family history of epilepsy; with the exception of a
single seizure of benign etiology (e.g. febrile seizure) in the judgment of the

- Chronic (particularly) uncontrolled medical conditions that may cause a medical
emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia,
asthma, etc.).

- Metal implants (excluding dental fillings) or devices such as pacemaker, medication
pump, nerve stimulator, Transcutaneous Electrical Nerve Stimulator (TENS) unit,
ventriculo-peritoneal shunt, cochlear implant, unless cleared by the study MD.

- Substance abuse or dependence within the past six months.

- Medications will be reviewed by the responsible MD and a decision about inclusion will
be made based on the following: The patient's past medical history, drug dose, history
of recent medication changes or duration of treatment, and combination of Central
Nervous System (CNS) active drugs.

- All female participants that are pre-menopausal will be required to have a pregnancy
test; any participant who is pregnant will not be enrolled in the study.

- BMI > 40 kg/m2. We will limit the BMI to <40 kg/m2 because of weight limits of the
scanner bed and width limits of the MRI.

- Subjects who, in the investigator's opinion, might not be suitable for the study

- A hair style or head dress that prevents electrode contact with the scalp or would
interfere with the stimulation (for example: thick braids, hair weave, afro, wig)
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557